Abstract
Facial erythema (the “red face”) is a straightforward clinical finding, and it is
evident even to the untrained eye; however, a red face does not represent a single
cutaneous entity. It may be due to a plethora of distinct underlying conditions of
varying severity, including rosacea, demodicosis, dermatomyositis, lupus erythematosus,
allergic contact dermatitis, drug-induced erythema, and emotional blushing. In clinical
practice, dermatologists do not encounter only one type of facial erythema but rather
a number of different shades of red. This review presents the clinical spectrum of
facial erythemas and addresses the question of what lies beneath a red face by discussing
the key clinical and histopathologic characteristics.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinics in DermatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Red face revisited: Flushing.Clin Dermatol. 2014; 32: 800-808
- Standard classification of rosacea: Report of the National Rosacea Society expert committee on the classification and staging of rosacea.J Am Acad Dermatol. 2002; 46: 584-587
- Cosmetics in rosacea.in: Zouboulis C.C. Katsambas A.D. Kligman A.M. Pathogenesis and Treatment of Acne and Rosacea. Springer, New York, NY2014: 717-727
- Optimizing the use of topical brimonidine in rosacea management: Panel recommendations.J Drugs Dermatol. 2015; 14: 33-40
- Understanding rosacea.Br J Dermtaol. 2015; 173: 635-636
- Facial erythema of rosacea: Aetiology, different pathophysiologies and treatment options.Acta Derm Venereol. 2016; 96: 579-586
- Rosacea.N Engl J Med. 2005; 352: 793-803
- Clinical and laboratory study of ocular rosacea in northern Greece.J Eur Acad Dermatol. 2011; 25: 1428-1431
- Ocular rosacea: Common and commonly missed.J Am Acad Dermatol. 2013; 69: s36-s41
- Ocular rosacea: A dermatologic perspective.J Am Acad Dermatol. 2013; 69: s42-s43
- Comparative analysis of rosacea and cutaneous lupus erythematosus: Histopathologic features, T-cells subsets, and plasmacytoid dendritic cells.J Am Acad Dermatol. 2014; 71: 100-107
- Rosacea under the microscope: Characteristic histological findings.J Eur Acad Dermatol. 2013; 27: 1336-1343
- Facial skin care products and cosmetics.Clin Dermatol. 2014; 32: 809-812
- The great mimickers of rosacea.Cutis. 2014; 94: 39-45
- Human demodicosis: Revisit and a proposed classification.Br J Dermatol. 2014; 178: 1219-1225
- Crusted rosacea-like demodicidosis in an HIV-positive female.J Am Acad Dermatol. 2011; 65: e131-e132
- Demodicosis: A clinicopathological study.J Am Acad Dermatol. 2009; 60: 453-462
- Papulopustular rosacea, skin immunity and Demodex: Pityriasis folliculorum as a missing link.J Eur Acad Dermatol Venereol. 2012; 26: 19-28
- Acneiform eruptions.Clin Dermatol. 2014; 32: 24-34
- Red face and fungi infection.Clin Dermatol. 2014; 32: 734-738
- Seborrheic dermatitis: Etiology, risk factors and treatments: Facts and controversies.Clin Dermatol. 2013; 31: 343-351
- Ulerythema ophryogenes: Updates and insights.Cutis. 2014; 93: 83-87
- Prevalence of acne rosacea in a rheumatic skin disease subspecialty clinic.Lupus. 1992; 1: 229-237
- Demodex mites in acne rosacea.J Cutan Pathol. 1998; 25: 550-552
- The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum. 1982; 25: 1271-1277
- Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus.Arthritis Rheum. 2012; 64: 2677-2686
- Interventions for rosacea: Abridged updated Cochrane systematic review including GRADE assessments.Br J Dermatol. 2015; 173: 651-662
- Brimonidine effective but may lead to significant rebound erythema.J Am Acad Dermatol. 2014; 70: e109-e110
- Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.J Am Acad Dermatol. 2014; 70: e37-e38
- Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea.J Am Acad Dermatol. 2014; 71: 832-833
- Mirvaso (brimonidine) 0.33% topical gel. Summary of product characteristics.(Available at:) (Accessed May 7, 2016)
Article info
Identification
Copyright
© 2016 Published by Elsevier Inc.
